Auris Medical Holding AG (EARS) Trading Down 4.2%
Auris Medical Holding AG (NASDAQ:EARS) shares traded down 4.2% on Tuesday . The company traded as low as $0.68 and last traded at $0.69. 555,928 shares were traded during mid-day trading, an increase of 70% from the average session volume of 327,863 shares. The stock had previously closed at $0.72.
A number of research analysts have recently weighed in on the company. Roth Capital restated a “buy” rating and issued a $5.00 target price on shares of Auris Medical Holding AG in a report on Saturday, July 1st. Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, August 30th. Finally, ValuEngine lowered Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $3.25.
The company has a 50 day moving average price of $0.76 and a 200 day moving average price of $0.76. The firm’s market cap is $30.77 million.
Auris Medical Holding AG (NASDAQ:EARS) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.09. Equities research analysts anticipate that Auris Medical Holding AG will post ($0.63) EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of the business. Virtu KCG Holdings LLC acquired a new position in shares of Auris Medical Holding AG in the second quarter worth about $101,000. Sabby Management LLC acquired a new position in shares of Auris Medical Holding AG in the first quarter worth about $133,000. Perceptive Advisors LLC acquired a new position in shares of Auris Medical Holding AG in the first quarter worth about $368,000. Finally, UBS Oconnor LLC acquired a new position in shares of Auris Medical Holding AG in the first quarter worth about $909,000. Institutional investors and hedge funds own 28.41% of the company’s stock.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.